Somewhat Positive Media Coverage Somewhat Unlikely to Impact NanoString Technologies (NSTG) Stock Price
News headlines about NanoString Technologies (NASDAQ:NSTG) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. NanoString Technologies earned a news impact score of 0.11 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.6689628533376 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have impacted Accern’s analysis:
- NanoString Technologies, Inc. (NSTG) Price Target Cut to $19.00 (americanbankingnews.com)
- NanoString Technologies, Inc. (NSTG) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- NanoString Announces Preliminary Revenue for Third Quarter of Fiscal Year 2017 (nasdaq.com)
- NanoString Announces Preliminary Revenue for Third Quarter of Fiscal Year 2017 (finance.yahoo.com)
- Analysts Anticipate NanoString Technologies, Inc. (NSTG) Will Announce Quarterly Sales of $27.54 Million (americanbankingnews.com)
NSTG has been the topic of several research reports. Janney Montgomery Scott lowered NanoString Technologies from a “buy” rating to a “neutral” rating in a research report on Thursday. Zacks Investment Research raised NanoString Technologies from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Wednesday, July 5th. ValuEngine raised NanoString Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, July 1st. Cowen and Company reaffirmed a “buy” rating on shares of NanoString Technologies in a research report on Friday, July 14th. Finally, BidaskClub lowered NanoString Technologies from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $19.00.
NanoString Technologies (NASDAQ NSTG) traded down 27.84% on Thursday, reaching $11.30. The company’s stock had a trading volume of 2,303,317 shares. The stock has a 50 day moving average price of $15.64 and a 200-day moving average price of $16.59. The company’s market capitalization is $284.81 million. NanoString Technologies has a 1-year low of $9.56 and a 1-year high of $23.45.
NanoString Technologies (NASDAQ:NSTG) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.17. NanoString Technologies had a negative net margin of 44.28% and a negative return on equity of 329.59%. The business had revenue of $34.59 million for the quarter, compared to analysts’ expectations of $29.87 million. Equities analysts predict that NanoString Technologies will post ($2.16) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact NanoString Technologies (NSTG) Stock Price” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/12/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-nanostring-technologies-nstg-stock-price.html.
NanoString Technologies Company Profile
NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.
Receive News & Stock Ratings for NanoString Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc. and related stocks with our FREE daily email newsletter.